Log In
Print
BCIQ
Print
Print this Print this
 

Abasria, Basaglar, insulin glargine (LY2963016)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionBasal insulin analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type I and II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type I and II diabetes);
EU - Biosimilar (Treat Type I and II diabetes);
EU - Standard Review (Treat Type I and II diabetes)
Partner Boehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,367.9M

$386.0M

$1,456.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today